Progress in active-specific immunotherapy of brain malignancies

Expert Opinion on Investigational Drugs

Volumn 9, Issue 9, 2000, Pages 2093-2101

  Tjoa, B A ^a   Salgaller, M L ^a  

^a Northwest Biotherapeutics Inc   (United States)

Author keywords

Brain tumour; Cancer vaccine; Dendritic cell; Glioblastoma; Glioma; Immunotherapy; T cell

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BETA INTERFERON; CANCER VACCINE; CARMUSTINE; CYTOKINE; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PLACEBO; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; BRAIN CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DENDRITIC CELL; DRUG EFFICACY; EFFECTOR CELL; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; MOUSE; NEUROSURGERY; NEUROTOXICITY; NONHUMAN; ONCOLOGY; OSMOTIC MINIPUMP; PROGNOSIS; RAT; REVIEW; SIDE EFFECT; VACCINATION; VACCINE PRODUCTION;

EID: 0033850207     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.9.2093     Document Type: Review

References (84)

1. Cancer statistics, 2000
2. The basis for current treatment recommendations for malignant gliomas
3. Biology and treatment of gliomas
4. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma
5. National survey of patterns of care for brain-tumor patients
6. Gliomas - Past, present and future
7. Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications
8. Intraoperative magnetic resonance imaging to update interactive navigation in neurosurgery: Method and preliminary experience
9. Glioblastoma multiforme
10. A randomised trial of interstitial radiotherapy (IRT) boost for treatment of newly diagnosed malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroma, malignant mixed glioma): BTCG study 8701
11. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: Prognostic factors and long-term outcome
12. Placebocontrolled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
13. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
14. Gene therapy for gliomas: Molecular targets, adenoviral vectors and oncolytic adenoviruses
15. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on surveillance, epidemiology and end results (SEER) data, 1973-1991
16. Spontaneous regression of non-Hodgkin's lymphoma. A report of nine cases
17. Clonal analysis of lymphocytes from tumor, peripheral blood and nontumorous kidney in primary renal cell carcinoma
18. Principles of chemotherapy
19. Immunologically privileged sites
20. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators
21. Immunopathogenic mechanisms in experimental allergic encephalomyelitis
22. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: A new view
23. Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells
24. Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+T cell priming and Th1/Th2 cell restimulation
25. Immune defects observed in patients with primary malignant brain tumors
26. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy
27. Inhibition of tumor necrosis factor alpha and beta secretion by lymphokine activated killer cells by transforming growth factor-β
28. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro
29. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors
30. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes
31. Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system
32. Human glioblastoma cells release interleukin 6 in vivo and in vitro
33. Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-alpha and/or interferon-gamma
34. Tumor necrosis factor-α induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis
35. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations
36. Tumor necrosis factor-a new therapeutic approach. Preclinical studies in nude mice
37. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
38. Addition of IFN-α to treatment of malignant brain tumors
39. Intravenous recombinant interferon β in patients with recurrent malignant gliomas: A Phase I/II study
40. Randomised, controlled study of intratumoral recombinant γ-interferon treatment in newly diagnosed glioblastoma
41. Clinical effect of intra-arterial tumor necrosis factor-α for malignant glioma
42. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α. Results of a Phase I clinical trial
43. 131 I-labeled anti-tenascin monoclonal antibody 81C6
44. Ganglioside GD2 specific monoclonal antibody 3F8: A Phase I study in patients with neuroblastoma and malignant melanoma
45. Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines
46. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14F(ab')2-a preliminary report
47. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results
48. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: A six-year clinical experience
49. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2
50. Intratumoral LAK cell and interleukin-2 therapy of human gliomas
51. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy
52. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors
53. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes
54. Systemic T cell adoptive immunotherapy of malignant gliomas
55. Glioblastoma multiforme: A controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy
56. Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: A pilot study
57. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system
58. Interleukin-12-based immunotherapy against rat 9L glioma
59. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression
60. Tumor antigens
61. Ganglioside vaccines with emphasis on GM2
62. Human gliomamesenchymal extracellular matrix antigen defined by monoclonal antibody
63. Expression of MAGE and GAGE in high-grade brain tumors: A potential target for specific immunotherapy and diagnostic markers
64. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas
65. Antigen-presenting cell types
66. Antigen processing for amateurs and professionals
67. The dendritic cell system and its role in immunogenicity
68. Dendritic cells as antigen presenting cells in vivo
69. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
70. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
71. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
72. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
73. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
74. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
75. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
76. The distinct surface of human blood dendritic cells, as observed after an improved isolation method
77. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood
78. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
79. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy
80. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-γ treatment
81. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
82. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms
83. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens
84. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma